Vermillion, Inc. (VRML) CFO Robert Harry Beechey Acquires 25,000 Shares of Stock

Vermillion, Inc. (NASDAQ:VRML) CFO Robert Harry Beechey bought 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 6th. The stock was purchased at an average cost of $0.57 per share, for a total transaction of $14,250.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Vermillion stock traded down $0.04 during mid-day trading on Friday, reaching $0.53. 6,997 shares of the company traded hands, compared to its average volume of 109,249. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.28 and a quick ratio of 5.23. Vermillion, Inc. has a 52-week low of $0.45 and a 52-week high of $2.10.

Vermillion (NASDAQ:VRML) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.04). The business had revenue of $0.77 million for the quarter. Vermillion had a negative net margin of 392.83% and a negative return on equity of 174.33%.

Institutional investors have recently modified their holdings of the business. Manatuck Hill Partners LLC purchased a new position in Vermillion during the 2nd quarter valued at $296,000. Lincoln National Corp increased its position in Vermillion by 331.5% during the 2nd quarter. Lincoln National Corp now owns 129,461 shares of the company’s stock valued at $101,000 after purchasing an additional 99,461 shares during the period. Finally, Vanguard Group Inc. increased its position in Vermillion by 16.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,452,612 shares of the company’s stock valued at $1,031,000 after purchasing an additional 209,600 shares during the period. 21.44% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Vermillion, Inc. (VRML) CFO Robert Harry Beechey Acquires 25,000 Shares of Stock” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at

Vermillion Company Profile

Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.

Read More: Using the New Google Finance Tool

Insider Buying and Selling by Quarter for Vermillion (NASDAQ:VRML)

Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with's FREE daily email newsletter.

Leave a Reply